Merck, Keytruda and Neck Cancers
Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. | The government price negotiations affecting Keytruda wouldn't take effect until 2028,
Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: It has been quietly happening in the ...
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...
Catherine Cooke is one of about 350 Kiwi women diagnosed with triple negative breast cancer each year. The only targeted treatment, the drug Keytruda, is u ...
Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback